Skip to main content
Home » Reports » Healthcare » Aerosol Delivery Devices Market
ReesrachMoz Brochure Icon

Global Aerosol Delivery Devices Market Analysis and Forecast 2019-2027

Report ID:531Healthcare225 pages

Aerosol Delivery Devices Market Statistics

The global aerosol delivery devices market is estimated to grow at a CAGR of 4.9% and reach the market valuation of USD 46.72bn in 2027as against its valuation of USD 31.46bn in 2019.

Aerosol drug devices are used in treating various diseases such as asthma, lung diseases, pneumonia, diabetes, etc. Its application in the treatment of several diseases acts as one of the major factors driving the aerosol drug delivery devices market over the forecast period.

The outbreak of the covid-19 pandemic had a positive impact on the aerosol delivery devices demand as the number of covid cases with respiratory complications had surged. Further, the onset of covid waves increased the demand for aerosol delivery devices in order to cater to public health.

Rising Prevalence of Obstructive Lung Diseases to Bolster Sales

Drug delivery through inhalation is the most common treatment for obstructive lung destructive which affects 15% of the U.S. population and is projected to pave the way for the growth of the global aerosol delivery devices market.

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death across the globe and reported 3.23 million deaths across the world, reports World Health Organization (WHO). This increasing prevalence of COPD is anticipated to bolster the sales of aerosol delivery devices market during the forecast period.

The aerosol drug delivery devices have undergone a sea of changes from 1956 to now in 2022, from just metred dose inhalers to many handheld devices such as dry powder inhalers, soft mist inhalers, etc. The increasing demand and rising patient population have led to a better understanding of the clinical application of the drug delivery among clinicians, thus nudging the growth in the global aerosol delivery market devices.

Global Aerosol Delivery Devices Market Share By Region Type

Patient Centricity to Uphold the Market Growth

The drug Delivery sector is projected to observe an upward growth due to growing importance being given to innovation and patient centricity.

The drug delivery device manufacturers and pharmaceutical companies are focusing on bringing a shift towards self-administration of drug delivery and giving the best and real-time experience to patients.

The pharma experts believe that innovations will accelerate in the coming years and the manufacturing and pharma companies including researchers are expected to work in tandem to use their expertise in confluence with digitalization, such as apps, computers, and phones. All these factors are foretold to boost the growth possibilities in the global aerosol delivery devices market.

Further, the growing geriatric population with severe respiratory diseases such as asthma, COPD, etc are predicted to increase the revenue of aerosol drug delivery devices.

However, side effects and high cost associated with aerosol delivery devices is likely to hinder the growth opportunities in the market during the forecast period.

Nonetheless, its applications in non-respiratory diseases such as Parkinson’s disease, diabetes, thyroid, and some genetic disorders could drive the global aerosol drug delivery market in the following years.

Data Points Market Insights
Market Value 2019 US$ 31.46 billion
Market Value 2027 US$ 46. 72billion
Market Growth Rate 2020-2027 4.9%
Top Regional Market Asia Pacific
Key Players Merck & co. INC., Metall Zug Group (Clement Clarke International Ltd), Koninklijke Philips N.V., 3M Company, Aerogen, INC, Recipharm AB (Bespak), Johnson & Johnson (Actelion Pharmaceuticals Ltd), Teva Pharmaceutical Industries Limited, Vectura Group PLC, Merxin LTD, Nemera, Iconovo AB, Gerresheimer AG
Segment Product Outlook, Metered Inhalers Outlook, Applications Outlook

Inhaled Drug Delivery to Stimulate Asthma Segment

Based on applications, the global aerosol delivery devices market is segmented into asthma, cystic fibroids, Chronic obstructive pulmonary disease, and non-respiratory diseases.

The asthma segment is foreseen to hold a larger share in the global aerosol market, under the inhaled drug delivery system, nebulizers are used largely as aerosol drug delivery devices. These nebulizers are used in metered-dose form to ease the distress in patients.

Inhalation therapy is the most common and preferred therapy in treating asthma, the National Institute of Health and Care Excellence and Global Initiative for chronic obstructive pulmonary diseases have been suggesting spreading awareness and training about inhaler devices as a part of disease management. The growing awareness and training are expected to drive the asthma segment where inhalers are highly used for disease management.

Based on product type, the global aerosol delivery devices market is bifurcated into – metered-dose inhalers, powder inhalers, nebulizers, and spay mist inhalers.

However, the dry powder inhalers segment is projected to boost the sales of the aerosol delivery device market in the years to follow. For better treatment and relief for the patients, the most effective route is, inhaling treatment.  However, on the basis of available products, the most preferred type is dry powdered inhalers due to their efficacy, a well-designed powdered inhaler offers efficient and systematic drug administration in patients. Therefore, the dry powdered inhalers segment under the product types is anticipated to thrive during the forecast period.

Among dry powdered inhalers, there are three types of line of treatment, the first being, unit devices, where a single unit of capsule containing powder is loaded, just before the use. The second type is multiple unit devices where a series of capsules are loaded to administer drugs to the patients and the last is reservoir unit devices, the powder is metered from the storage unit. Of all of these, the most preferred are multiple units and reservoir types, such as Accuhaler and Turbuhaler respectively, as they can be used for many weeks for treatment. These factors are foreseen to augment the dry powder inhaler segment in the global aerosol delivery devices market over the forecast period.

The Asia Pacific to Lead the Global Aerosol Delivery Devices Market

The global aerosol delivery devices market is expected to be dominated by the Asia Pacific, the growth in the region can be attributed to the growing adult population that is susceptible to diseases like asthma, COPD, Pneumonia, etc. Further, growing investment in research and development to leverage technology for innovation in products line for promoting self-administration among patients could strengthen the Asia Pacific region over the forecast period.

Moreover, the prevalence of asthma in developing economies such as India, China, and Japan is projected to drive growth in the region. Also, the growing geriatric population with COPD and other respiratory disorders may boost the growth in the region.

Competitive Landscape

In March 2022, Astrazenecaa announced the launch of global research and development postdoctoral challenge where the PhD students and researchers are invited to outpour and share innovative ideas to accelerate drug delivery and development in the areas of treatment of core diseases.

In April 2022, Novartis announces to expand its Zongelsma manufacturing capacity with approval from Food and Drug Administration, a multi-product gene therapy facility. The facility will test and release commercial Zolgensma and also be manufacturing gene therapy for existing and future clinical trials.

In 2020, GlaxoSmithKline and the University of Oxford together launched a new Oxford-GSK institute to harness the advanced technology for a deep understanding of diseases such as Alzheimer’s and Parkinson’s to fasten the drug delivery and treatment success rates.

Aerosol Delivery Devices Market Segmentation

Product Outlook

  • Dry powder inhalers
  • Single-dose inhalers
  • Multi-dose inhalers
  • Reservoir Inhalers

Metered-dose inhalers

  • Conventional pressurized inhalers,
  • Soft mist inhalers
  • Nebulizers
  • Jet nebulizers
  • Ultrasonic wave nebulizers
  • Vibrating mesh nebulizers

Application Outlook

  • Asthma
  • Chronic obstructive pulmonary disease
  • Cystic fibrosis

Non-respiratory diseases

  • Diabetes
  • Analgesia
  • Parkinson’s disease

Key Players

  • GlaxoSmithKline Plc (GSK)
  • Merck & co., INC.
  • Metall Zug Group (Clement Clarke International Ltd)
  • Koninklijke Philips N.V.
  • 3M Company
  • Aerogen, INC
  • Recipharm AB (Bespak)
  • Johnson & Johnson (Actelion Pharmaceuticals Ltd)
  • Teva Pharmaceutical Industries Limited
  • Vectura Group PLC
  • Merxin LTD
  • Nemera
  • Iconovo AB
  • Gerresheimer AG

Frequently Asked Questions

What is the growth rate of the global aerosol delivery devices market?

The global aerosol delivery devices market by 4.9% between 2019 to 2027

What are the factors that drive the global aerosol delivery devices market during the forecast period?

The increasing prevalence of COPD and other respiratory diseases is projected to drive the global aerosol delivery devices market.

Which segment under applications would thrive over the forecast period?

The asthma segment will hold a major share in the global aerosol delivery devices market during the forecast period.

Which region will dominate the global aerosol delivery devices market in the coming years?

Asia Pacific will lead the global aerogel insulation market over the next few years.

Table Of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics

4. Global Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis

5. Global Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Product, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Product, 2022-2032
5.3.1. Dry powder inhalers
5.3.1.1. Single-dose inhalers
5.3.1.2. Multi-dose inhalers
5.3.1.3. Reservoir Inhalers
5.3.2. Metered-dose inhalers
5.3.2.1. Conventional pressurized inhalers,
5.3.2.3. Soft mist inhalers
5.3.3. Nebulizers
5.3.3.1. Jet nebulizers
5.3.3.2. Ultrasonic wave nebulizers
5.3.3.3. Vibrating mesh nebulizers
5.4. Y-o-Y Growth Trend Analysis By Product, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product, 2022-2032

6. Global Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Application, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Application, 2022-2032
6.3.1. Asthma
6.3.2. Chronic obstructive pulmonary disease
6.3.3. Cystic fibrosis
6.3.4. Non-respiratory diseases
6.3.4.1. Diabetes
6.3.4.2. Analgesia
6.3.4.3. Parkinson’s disease
6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
6.5. Absolute $ Opportunity Analysis By Application, 2022-2032

7. Global Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Based on End Use
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Based on End Use, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Based on End Use, 2022-2032
7.4. Y-o-Y Growth Trend Analysis By Based on End Use, 2017-2021
7.5. Absolute $ Opportunity Analysis By Based on End Use, 2022-2032

8. Global Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region

9. North America Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Product
9.2.3. By Application
9.2.4. By Based on End Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Application
9.3.4. By Based on End Use
9.4. Key Takeaways

10. Latin America Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Argentina
10.2.1.4. Chile
10.2.1.5. Peru
10.2.1.6. Rest of Latin America
10.2.2. By Product
10.2.3. By Application
10.2.4. By Based on End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Application
10.3.4. By Based on End Use
10.4. Key Takeaways

11. Europe Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. Russia
11.2.1.7. BENELUX
11.2.1.8. Rest of Europe
11.2.2. By Product
11.2.3. By Application
11.2.4. By Based on End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Application
11.3.4. By Based on End Use
11.4. Key Takeaways

12. East Asia Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Product
12.2.3. By Application
12.2.4. By Based on End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Application
12.3.4. By Based on End Use
12.4. Key Takeaways

13. South Asia Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Thailand
13.2.1.3. Malaysia
13.2.1.4. Indonesia
13.2.1.5. Rest of South Asia
13.2.2. By Product
13.2.3. By Application
13.2.4. By Based on End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Application
13.3.4. By Based on End Use
13.4. Key Takeaways

14. Oceania Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Product
14.2.3. By Application
14.2.4. By Based on End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Application
14.3.4. By Based on End Use
14.4. Key Takeaways

15. MEA Aerosol Delivery Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
15.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
15.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
15.2.1. By Country
15.2.1.1. GCC
15.2.1.2. Rest of MEA
15.2.2. By Product
15.2.3. By Application
15.2.4. By Based on End Use
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Application
15.3.4. By Based on End Use
15.4. Key Takeaways

16. Key Countries Aerosol Delivery Devices Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2021
16.1.2.1. By Product
16.1.2.2. By Application
16.1.2.3. By Based on End Use
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2021
16.2.2.1. By Product
16.2.2.2. By Application
16.2.2.3. By Based on End Use
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2021
16.3.2.1. By Product
16.3.2.2. By Application
16.3.2.3. By Based on End Use
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2021
16.4.2.1. By Product
16.4.2.2. By Application
16.4.2.3. By Based on End Use
16.5. Argentina
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2021
16.5.2.1. By Product
16.5.2.2. By Application
16.5.2.3. By Based on End Use

17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1.  By Regional
17.3.2.  By Product
17.3.3.  By Application
17.3.4.  By Based on End Use

18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. GlaxoSmithKline Plc (GSK)
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Merck & co., INC.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Metall Zug Group (Clement Clarke International Ltd)
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Koninklijke Philips N.V.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. 3M Company
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Aerogen, INC
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Recipharm AB (Bespak)
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Teva Pharmaceutical Industries Limited
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Vectura Group PLC
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
18.1.11. Merxin LTD
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.11.5.2. Product Strategy
18.1.11.5.3. Channel Strategy
18.1.12. Nemera
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.12.5.2. Product Strategy
18.1.12.5.3. Channel Strategy
18.1.13. Iconovo AB
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.13.5.2. Product Strategy
18.1.13.5.3. Channel Strategy
18.1.14. Gerresheimer AG
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
18.1.14.5.2. Product Strategy
18.1.14.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Request Free Sample

Hidden
Company logos Strips